Status:

COMPLETED

Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Abnormal Contraction or Twitch of the Eyelid

Lead Sponsor:

Merz Pharmaceuticals GmbH

Conditions:

Bilateral Blepharospasm (BEB)

Eligibility:

All Genders

18-80 years

Phase:

PHASE3

Brief Summary

This phase 3 study will serve to collect efficacy and safety data of two different doses of NT 201 in subjects suffering from Bilateral Blepharospasm (BEB) who are BTX treatment-naïve. In this study,...

Detailed Description

Subjects to receive one injection with NT 201 or placebo at baseline of the placebo-controlled first cycle. Thereafter, all subjects entering the Open-Label Extension Period (OLEX) to receive a second...

Eligibility Criteria

Inclusion

  • Male or female out-patients age ≥ 18 and ≤ 80 years.
  • A clinical diagnosis of bilateral BEB characterized by spontaneous, spasmodic, intermittent or persistent involuntary contractions of orbicular oculi muscles.
  • A need for injection of BTX defined as a Jankovic Rating Scale \[JRS\] severity subscore ≥ 2.
  • Treatment-naïve subject defined as at least 12 months without BTX of any serotype for the treatment of BEB before administration of IP.

Exclusion

  • Subject with any previous unsuccessful treatment with BTX of any serotype for the treatment of BEB.
  • Atypical variant of BEB (e.g., apraxia of the eyelid opening) caused by inhibition of levator palpebrae muscle.
  • Neuroleptic-induced blepharospasm.
  • Myotomy or denervation surgery in the affected muscles (e.g., peripheral denervation, spinal cord stimulation) and surgery in the upper face.
  • Generalized disorders of muscles activity (e.g., myasthenia gravis in particular ocularis, Lambert-Eaton-Syndrome, amyotrophic lateral sclerosis) or any other significant neuromuscular dysfunction which might interfere with the study.

Key Trial Info

Start Date :

November 1 2013

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 1 2016

Estimated Enrollment :

61 Patients enrolled

Trial Details

Trial ID

NCT01896895

Start Date

November 1 2013

End Date

November 1 2016

Last Update

March 1 2018

Active Locations (11)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (11 locations)

1

Merz Investigational Site #030002

Athens, Greece, 11521

2

Merz Investigational Site #030001

Athens, Greece, 11526

3

Merz Investigational Site #060007

George Town, Pulau Pinang, Malaysia, 10990

4

Merz Investigational Site #060004

Kota Kinabalu, Sabah, Malaysia, 88586